安络化纤丸联合拉米夫定治疗早中期乙肝肝硬化疗效观察

Curative effect observation of An Luo Hua Xian Pill combined with lamivudine in treatment of early stage liver cirrhosis

目的:探讨在早中期乙肝肝硬化患者中应用安络化纤丸联合拉米夫定的临床疗效。方法:2012年7月-2014年6月收治早中期乙肝肝硬化患者80例,随机分为对照组(40例)和观察组(40例)。对照组服用拉米夫定,观察组同时服用安络化纤丸和拉米夫定。观察两组患者的临床治疗效果。结果:两组在HBV-DNA转阴率上没有明显差异,但观察组治疗后球蛋白和丙氨酸氨基转移酶明显低于对照组,肝纤维化指标明显低于对照组,差异具有统计学意义(P<0.05)。结论:对早中期乙肝肝硬化患者应用安络化纤丸联合拉米夫定的治疗方案,临床疗效良好,患者肝功能恢复情况更佳,提高了患者的生存质量,值得临床推广。

Objective:To explore the curative effect of An Luo Hua Xian Pill combined with lamivudine in treatment of early stage liver cirrhosis.Methods:80 cases of early mid stage patients with liver cirrhosis were selected from July 2012 to June 2014.They were randomly divided into the control group(40 cases) and the observation group(40 cases).The control group were treated with lamivudine.The observation group were treated with An Luo Hua Xian Pill and lamivudine.We observed the clinical efficacy of two groups.Results:In the HBV-DNA negative rate,the two groups had no obvious difference,but after treatment,in the observation group,globulin and alanine aminotransferase were significantly lower than the control group;liver fibrosis index was significantly lower than the control group;the difference was statistically significant(P<0.05).Conclusion:The curative effect of An Luo Hua Xian Pill combined with lamivudine in treatment of early stage liver cirrhosis is good.Liver function recovery is better.It improves the life quality of the patients.It is worthy of clinical application.